US FDA observations may hit Shilpa Medicare

Shares of Shilpa Medicare may come under pressure, as the company has received observations from the United States Food & Drug Administration in relation to its SEZ formulation facilities situated at Jadcherla, Telangana. Ten observations were cited during the close-up meetings — seven were for improvement in procedures and practices and three related to setting of analytical specifications, test procedures and method validation, it added.